Ellen Duong

781 total citations · 1 hit paper
17 papers, 464 citations indexed

About

Ellen Duong is a scholar working on Oncology, Immunology and Virology. According to data from OpenAlex, Ellen Duong has authored 17 papers receiving a total of 464 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 12 papers in Immunology and 3 papers in Virology. Recurrent topics in Ellen Duong's work include Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (8 papers). Ellen Duong is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Immunotherapy and Immune Responses (8 papers) and Immune Cell Function and Interaction (8 papers). Ellen Duong collaborates with scholars based in United States. Ellen Duong's co-authors include Stefani Spranger, Emi A. Lutz, K. Dane Wittrup, Teresa Dinter, Tim Fessenden, Leon Yim, Sarah E. Blatt, Arjun Bhutkar, Yuan Cao and Carthene R. Bazemore‐Walker and has published in prestigious journals such as Proceedings of the National Academy of Sciences, SHILAP Revista de lepidopterología and Immunity.

In The Last Decade

Ellen Duong

17 papers receiving 458 citations

Hit Papers

Type I interferon activates MHC class I-dressed CD11b+ co... 2021 2026 2022 2024 2021 50 100 150 200

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ellen Duong United States 10 311 183 153 45 35 17 464
Chungyong Han South Korea 11 166 0.5× 138 0.8× 107 0.7× 23 0.5× 22 0.6× 20 309
Simone P. Sittig Netherlands 11 538 1.7× 195 1.1× 204 1.3× 34 0.8× 10 0.3× 11 670
Ralf Sanzenbacher Germany 10 176 0.6× 59 0.3× 186 1.2× 42 0.9× 21 0.6× 19 345
Morvarid Moayeri United States 10 167 0.5× 296 1.6× 254 1.7× 19 0.4× 9 0.3× 21 584
Benita Wolf Switzerland 12 186 0.6× 208 1.1× 124 0.8× 24 0.5× 8 0.2× 23 401
Nicole Lévy Switzerland 7 334 1.1× 151 0.8× 217 1.4× 37 0.8× 10 0.3× 9 511
Frank Fasbender Germany 9 351 1.1× 162 0.9× 78 0.5× 55 1.2× 10 0.3× 9 474
Howard J. Leung United States 7 193 0.6× 102 0.6× 264 1.7× 58 1.3× 20 0.6× 8 410
Sarah Fritchley United Kingdom 8 217 0.7× 230 1.3× 173 1.1× 29 0.6× 41 1.2× 9 476
Keisuke Kohga Japan 13 379 1.2× 221 1.2× 156 1.0× 107 2.4× 8 0.2× 18 601

Countries citing papers authored by Ellen Duong

Since Specialization
Citations

This map shows the geographic impact of Ellen Duong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ellen Duong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ellen Duong more than expected).

Fields of papers citing papers by Ellen Duong

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ellen Duong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ellen Duong. The network helps show where Ellen Duong may publish in the future.

Co-authorship network of co-authors of Ellen Duong

This figure shows the co-authorship network connecting the top 25 collaborators of Ellen Duong. A scholar is included among the top collaborators of Ellen Duong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ellen Duong. Ellen Duong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Whittaker, Charles A., et al.. (2025). Lung Cancer–Intrinsic SOX2 Expression Mediates Resistance to Checkpoint Blockade Therapy by Inducing Treg-Dependent CD8+ T-cell Exclusion. Cancer Immunology Research. 13(4). 496–516. 2 indexed citations
2.
Nutsch, Katherine, Karl L. Banta, Thomas D. Wu, et al.. (2024). TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation. Nature Cancer. 5(12). 1834–1851. 16 indexed citations
3.
Guan, Xiangnan, Ruozhen Hu, Yoonha Choi, et al.. (2024). Anti-TIGIT antibody tiragolumab improves PD-L1 blockade via myeloid and Treg cells. The Journal of Immunology. 212(1_Supplement). 0516_5297–0516_5297. 1 indexed citations
4.
Lutz, Emi A., Yash Agarwal, Noor Momin, et al.. (2022). Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies. Proceedings of the National Academy of Sciences. 119(36). e2205983119–e2205983119. 23 indexed citations
5.
Duong, Ellen, Tim Fessenden, Emi A. Lutz, et al.. (2021). Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunity. Immunity. 55(2). 308–323.e9. 233 indexed citations breakdown →
6.
Duong, Ellen, Emi A. Lutz, Teresa Dinter, et al.. (2021). 683 Type-I-interferon activates cross-dressed CD11b+conventional dendritic cells to enhance anti-tumor immunity. SHILAP Revista de lepidopterología. A711–A711. 2 indexed citations
7.
Elpek, Kutlu G., Ellen Duong, Martin Fan, et al.. (2020). ICOS agonism by JTX-2011 (vopratelimab) requires initial T cell priming and Fc cross-linking for optimal T cell activation and anti-tumor immunity in preclinical models. PLoS ONE. 15(9). e0239595–e0239595. 23 indexed citations
8.
Zagorulya, Maria, Ellen Duong, & Stefani Spranger. (2020). Impact of anatomic site on antigen-presenting cells in cancer. Journal for ImmunoTherapy of Cancer. 8(2). e001204–e001204. 19 indexed citations
9.
Michaelson, Jennifer S., Christopher J. Harvey, Kutlu G. Elpek, et al.. (2017). Abstract SY03-02: Preclinical assessment of JTX-2011, an agonist antibody targeting ICOS, supports evaluation in ICONIC clinical trial. Cancer Research. 77(13_Supplement). SY03–2. 2 indexed citations
10.
Elpek, Kutlu G., Christopher J. Harvey, Ellen Duong, et al.. (2016). Abstract A059: Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Cancer Immunology Research. 4(1_Supplement). A059–A059. 1 indexed citations
11.
Michaelson, Jennifer S., Christopher J. Harvey, Kutlu G. Elpek, et al.. (2016). Abstract 573: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody. Cancer Research. 76(14_Supplement). 573–573. 1 indexed citations
12.
Duong, Ellen, et al.. (2015). Variable Processing and Cross-presentation of HIV by Dendritic Cells and Macrophages Shapes CTL Immunodominance and Immune Escape. PLoS Pathogens. 11(3). e1004725–e1004725. 31 indexed citations
13.
Harvey, Christopher J., Kutlu G. Elpek, Ellen Duong, et al.. (2015). Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics. Journal for ImmunoTherapy of Cancer. 3(S2). 10 indexed citations
14.
Lai, Nicole Y., Ellen Duong, Marijana Ručević, et al.. (2014). Different Antigen-Processing Activities in Dendritic Cells, Macrophages, and Monocytes Lead to Uneven Production of HIV Epitopes and Affect CTL Recognition. The Journal of Immunology. 193(9). 4322–4334. 18 indexed citations
15.
Lai, Nicole Y., et al.. (2013). A simple methodology to assess endolysosomal protease activity involved in antigen processing in human primary cells. BMC Cell Biology. 14(1). 35–35. 16 indexed citations
16.
Boucau, Julie, et al.. (2013). A real-time killing assay to follow viral epitope presentation to CD8 T cells. Journal of Immunological Methods. 398-399. 60–67. 5 indexed citations
17.
Duong, Ellen, et al.. (2011). Proteomic analysis of lipid raft-enriched membranes isolated from internal organelles. Biochemical and Biophysical Research Communications. 415(2). 355–360. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026